Table 1 Baseline clinicopathological characteristics, n = 68.
Characteristic, n = 68 | n (%) | |
|---|---|---|
Age (years) | Mean/median (range) | 64/65 (47–76) |
Gender | Male | 58 (85) |
Smoking (current or past) | Yes | 52 (76) |
cT category (TUR-BT’) | T2 | 48 (71) |
T3 | 18 (27) | |
T4 | 2 (3) | |
CIS1 (TUR-BT’) | Yes | 15 (22) |
LVI2 (TUR-BT’) | Yes | 17 (25) |
Tumor size (mm) (TUR-BT’) | Mean/median (range) | 23/19 (1–70) |
pT category (RC”) | T0 | 28 (41) |
pTa, pTcis, pT1 | 15 (22) | |
pT2 | 10 (15) | |
pT3 | 10 (15) | |
pT4 | 5 (7) | |
pN category (RC”) | Positive | 7 (11) |
Negative | 58 (89) | |
Neoadjuvant chemotherapy | Cisplatin-Gemcitabine | 64 (94) |
Carboplatin-Gemcitabine | 4 (6) | |
Chemotherapy cycles (number) | Mean/median (range) | 3/4 (2–6)3 |
Adjuvant chemotherapy | Yes | 6 (9) |
Follow-up time (years) | Mean/median (range) | 3.3/3.6 (0.25–7.7) |
Status | Alive, no evidence of disease | 53 (78) |
Death due bladder cancer | 13 (19) | |
Death due other reason | 2 (3) | |
Pathological response to the neoadjuvant chemotherapy | Complete response (pT0) | 28 (41) |
Partial response (pT1/pTa/pTis) | 14 (21) | |
No response | 9 (13) | |
Progression (pT3 and/or N+) | 17 (25) |
